As per the latest data released by Transforming Access to Student Outcomes in Higher Education (TASO) and the Policy Institute at King's College London, the number of UK students reporting mental health difficulties tripled. The estimate reveals that around 300,000 students could now be experiencing mental health struggles. Of the total, 18% of students reported some kind of mental health issue in 2024.

As per the reports, this estimate is triple what was reported in 2017, where it was at 6%. Experts also say that Covid-19 pandemic is "often considered to have contributed to this, it does not explain the ongoing rise in mental health difficulties." Another reason could also be the "changing definition and increasing openness about mental health" which has led to a rise in numbers. The report notes, "This trend pre-dates the Covid-19 pandemic and the cost-of-living crisis. Although these factors play a part in students' deteriorating mental health, they cannot therefore be the only explanation."

How Did The Report Conclude?

The report drew data collected over the latest Student Academic Experience Survey of 93,212 students. From the survey, it was found that there exist significant disparities between demographic groups, with women being twice as likely to report mental health difficulties, about 22% as compared to men, at 11%.

What Did The Results Reveal?

The results revealed that students who identified as LGBTQ experienced the highest rates of mental health challenges. This has actually lessened the hope that conditions for LGBTQ students are improving, which may not have been a positive case.

Of them, 42% are bisexual and lesbian students, whereas last year it was 35% and 32% respectively. The report also noted that mental health difficulties among lesbian women and gay men rose three times the rate of straight people, and among bisexual and asexual people, it was twice as high. For trans students, the number jumped from 25% in 2023 to 40% in 2024.

Is The LGBTQ+ Prone To Mental Health Crisis?

As per the Child Mind Institute, being LGBTQ+ does not cause mental health problems, but because these kids often face factors like rejection, discrimination and violence, they are at a higher risk of challenges including depression, anxiety, and even attempting suicide.

A UTAH Health study quotes Anna Docherty, PhD, LP, assistant professor of psychiatry at Huntsman Mental Health Institute that, "likely with any identity, feeling different - or worse, unaccepted as you are is a significant risk factor of mental health struggle." The data reveals that LGBTQ+ teens are six times more likely to experience symptoms of depression than non-LGBTQ+ identifying teens. They are also more than twice as likely to feel suicidal and more than four times as likely to attempt suicide. In the US alone, 48% of transgender adults report that they have considered suicide in the last year, compared to 4% of the overall population.

What Do These Findings Mean?

TASO's academic lead and professor of public policy at King's College London, Michael Sanders said, "LGBTQ students and women bear the brunt of the rise in declining mental health and urgent action is needed to understand and address these trends."

GLP-1 medications have shown significant promise in treating obesity and type 2 diabetes in adults. Their use has also expanded among children with obesity. However, a new study found that nearly 1 in 6 children, or 17%, treated with GLP-1 medications developed a diagnosed nutritional deficiency within one year.

The research, conducted by scientists at Northwestern University and Ann & Robert H. Lurie Children’s Hospital of Chicago, found that vitamin D deficiency was the most common nutritional deficiency, identified in 12.4% of children within one year of starting GLP-1 treatment.

“As appropriate pediatric use of GLP-1s becomes more widespread, we need to understand the risks during periods of rapid growth and pubertal development,” said senior author Justin Ryder, associate professor of surgery and pediatrics at Northwestern University Feinberg School of Medicine.

“Nutrients such as vitamin D, iron and calcium are of particular concern during adolescence, when deficiencies may have lasting implications for skeletal health and overall development,” the expert added. The study was published in the journal Childhood Obesity.

Only a Small Share Received Nutritional Counselling

According to Ryder, nutritional support is key once treatment with a GLP-1 medication is initiated.

However, the study found that only 5% of patients received nutritional counseling within 30 days of starting GLP-1 treatment, while less than 25% received nutritional counseling within six months.

Key Findings

The scientists used national administrative claims data from 2017 to 2022 covering more than 100 million patients. They identified 2,031 GLP-1 users aged 10–17 who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.

Among these children, the most commonly prescribed GLP-1 medications were liraglutide (78.6%), dulaglutide (10.4%) and semaglutide (9.1%).

The researchers said proactive nutritional management is important when GLP-1 medications are prescribed to children, rather than waiting until a nutritional deficiency is diagnosed.

GLP-1 Prescriptions Rising For Children Under 12

The new study comes as the use of GLP-1 medications among younger children has been rising in the US, although their use for obesity in this age group remains limited and varies by medication. The FDA has approved GLP-1 treatment for obesity in adolescents, among those age 12.

A recent study from NYU Langone Health, based on health records from more than 3.5 million children aged 8 to 11 with obesity in the US, found that prescriptions for GLP-1 medications increased more than 300-fold between 2019 and June 2026.

In 2019, about 0.03% of children in the study group had been prescribed a GLP-1 drug. By June 2026, that figure had risen to 9.3%.

The medications included drugs such as Wegovy and Saxenda, made by Novo Nordisk, and Eli Lilly's Zepbound.

Among children receiving GLP-1 medications, 94% had severe obesity, while about 65% had obesity-related health conditions, including high blood pressure or sleep apnea.

GLP-1 Drugs and FDA Approval for Younger Children

The FDA has approved certain GLP-1 medications for obesity in some pediatric age groups, but the approvals and age limits vary by drug. The GLP-1 medications included in the under-12 study are not generally FDA-approved for weight management in children younger than 12.

However, doctors can prescribe medicines off-label when they believe there is a medical reason to do so. Clinical guidelines may also support the use of obesity medications in certain circumstances involving younger children.

India’s Central Drugs Standard Control Organisation (CDSCO) has issued an advisory cautioning against the indiscriminate use of painkillers and antibiotics.

It warned that inappropriate or prolonged use of these medicines can lead to kidney complications and contribute to antimicrobial resistance.

This comes as a Parliamentary Standing Committee on Health and Family Welfare recently noted that the pooled prevalence of chronic kidney disease (CKD) in India is approximately 13.24%.

The committee suggested that people above 20 undergo kidney function testing every six months.

How Can Painkillers Affect Kidneys?

“NSAIDs/painkillers and antibiotics should not be taken indiscriminately, repeatedly or for prolonged periods without medical advice,” the CDSCO said.

• NSAIDs can increase the risk of renal impairment, particularly in people with existing kidney disease or other risk factors.
• The risk is greater with repeated or prolonged use.
• People with renal impairment, dehydration or cardiovascular disease require particular caution when using NSAIDs.

It also suggested them to seek medical advice if pain, fever or other symptoms persist or recur, instead of repeatedly using painkillers or antibiotics on your own.

Further, the CDSCO noted that antibiotics should not be used for self-medication or for conditions where they are not clinically indicated, such as most uncomplicated viral infections.

Prescribed antibiotics should be taken strictly as advised and should not be shared or used from leftover medicines.

“Antibiotics prescribed by a healthcare professional should be taken strictly as advised and should not be shared with other persons or used from leftover medicines.”

What CDSCO Told Doctors

Also read: Young Americans Are Developing Kidney Failure Without Usual Risk Factors: What Is CKDu?

Healthcare practitioners have been advised to prescribe NSAIDs and antibiotics only when clinically indicated, after considering the patient’s:

• Clinical condition
• Age
• Co-morbidities
• Concomitant medicines
• Relevant risk factors

“The lowest effective dose for the shortest appropriate duration should be considered when prescribing NSAIDs, particularly in patients at increased risk of renal impairment.”

Doctors have also been advised to take appropriate precautions when prescribing NSAIDs to people with:

• Renal impairment
• Dehydration
• Cardiovascular disease
• Other conditions that may increase the risk associated with NSAID use

Antibiotics should be prescribed judiciously in line with antimicrobial stewardship principles. Unnecessary combination therapy, inappropriate antibiotic selection, incorrect dosing and unnecessarily prolonged treatment should be avoided.

Hospitals Asked To Strengthen Monitoring

The CDSCO has asked hospitals and healthcare institutions to:

• Strengthen systems for rational prescribing and monitoring of NSAIDs and antibiotics
• Promote antimicrobial stewardship
• Conduct prescription reviews
• Provide appropriate patient counselling.

What CDSCO Told Pharmacies

The regulator has directed pharmacies and retailers to strictly comply with rules governing the sale and distribution of prescription medicines.

• Schedule H, H1 and other prescription drugs must be sold in accordance with applicable provisions of the Drugs Rules, 1945.
• Pharmacists and retailers should not encourage or facilitate self-medication with antibiotics or prescription-only NSAIDs.
• Prescribed warnings and conditions of sale on medicine labels must be followed.
• Schedule H1 drugs should not be sold at retail except in accordance with the applicable provisions of the Drugs Rules, 1945.

NSAIDs, Antibiotics Require Medical Supervision

The CDSCO said that various drugs, including NSAIDs and antibiotics, are placed under Schedules G, H, H1 and X of the Drugs Rules, 1945.

Most NSAIDs are included in Schedule H and are not to be sold at retail without a prescription from a Registered Medical Practitioner. Similarly, most antibiotics are included in Schedule H1.

They are required to carry the following warnings:

• It is dangerous to take this preparation except in accordance with the medical advice.
• Not to be sold by retail without the prescription of a Registered Medical Practitioner.

At least six major hospitals in the US have made deals with the Department of Justice to refuse gender-affirming hormones and surgery for young transgender individuals. The move has marked quite an escalation in the federal government's effort to restrict gender-affirming care across the country.

The latest agreements, announced on September 18, involve New York University Langone Health and the University of Pittsburgh Medical Center (UPMC). They follow Mount Sinai Health System, Connecticut Children's Medical Center, Cleveland Clinic Foundation and Texas Children's Hospital.

Under the agreements, the hospitals will not provide puberty blockers, cross-sex hormones or gender-affirming surgeries to patients under 18.

The DOJ uses the term "sex-rejecting procedures" for these treatments, while medical organisations and healthcare providers generally use the term gender-affirming care.

Why Is The DOJ Targeting These Hospitals?

Also read: CDC Youth Report: US Teen Mental Health, Suicide Risk Improve; Sleep, Low Exercise Remain Concerns

The agreements stem from a nationwide investigation by the Justice Department that was launched after President Donald Trump directed the DOJ in 2025 to prioritise investigations involving gender-affirming care for minors.

The DOJ says it is examining potential violations of the Food, Drug, and Cosmetic Act, False Claims Act and other federal healthcare laws, including allegations that providers used false diagnosis codes to obtain insurance or government payments for treatments.

The DOJ has also subpoenaed hospitals for information about patients who received gender-affirming care, including sensitive medical records.

Attorney General Todd Blanche said the DOJ is "fighting to protect our nation's children" and working to reach agreements with hospitals to end what the administration calls gender-affirming care for minors.

However, the legal status of the allegations cannot be neglected. The DOJ itself says the claims resolved through these agreements are just allegations and that there has been no determination of any kind of liability. NYU and UPMC have denied the allegations.

NYU And UPMC Deals

Also read: ‘Life-Saving’ Martha’s Rule To Expand To Emergency Departments Across England: What It Means

NYU Langone agreed to pay the federal government $8.5 million, while UPMC has agreed to pay $950,000. Both have agreed to stop providing gender-affirming medical treatments to minors.

The settlements also resolve the DOJ investigations and protect confidential information involving patients, families and healthcare providers that had been sought through earlier subpoenas.

NYU had already stopped its transgender youth programme in February, citing the "current regulatory environment." However, its agreement with DOJ does not affect its pediatric mental-health programmes transgender children. Similarly, UPMC's agreement applies to patients under 18.

Other Hospitals That Have Agreed

The six hospital systems that have agreed to the DOJ deals are:

1. Texas Children's Hospital, in May 2026, ended specified treatments worth more than $10 million in payments/damages and penalties
2. In June this year, Cleveland Clinic, agreed to end specified pediatric treatments
3. In August, Connecticut Children's stopped treatments and incurred monetary penalty and $500,000 for medical care
4. Mount Sinai Health System, in September 2026, too ended care and paid monetary penalty and $2 million for medical care
5. NYU Langone, stopped treatments and care in September and bore $8.5 million payment
6. UPMC, too, ended treatments and paid $950,000 in the deals

These agreements apply to the individual hospital systems that signed them. They do not by themselves create a nationwide federal ban on gender-affirming care for minors. Some states have enacted restrictions on gender-affirming care for minors, while other states have laws protecting access to such care.

The agreements generally concern future provision of gender-affirming treatment to minors. They do not eliminate the hospitals' overall pediatric mental-health care services.

The settlements demonstrate how the DOJ investigation has created a difficult choice for hospitals. They can either fight the government's allegations in court and reveal sensitive patient information or reach an agreement that ends the investigation while restricting the treatments in question.

NYU said its agreement was intended to protect patient from prolonged litigation and to preserve their confidentiality. The six settlements therefore represent more than individual hospital policy changes. They show how the Trump administration is using federal investigations, healthcare-fraud laws and settlement agreements to influence access to gender-affirming care for minors.